LIVE VIRTUAL • MARCH 12-15, 2021

9th Annual

Hematology and Medical Oncology Board Review

CONTEMPORARY PRACTICE

Memorial Sloan Kettering Cancer Center
This four day virtual course will provide an up-to-date and comprehensive review of the diagnosis, staging, and management of neoplastic disease, including solid tumor and hematologic oncology.

Lectures will focus on disease specific topics in gastrointestinal, gynecologic, thoracic, head and neck, genitourinary, soft tissue and skin, and central nervous system oncology, as well as hematologic oncology.

By attending this board review, attendees will:

• Learn state-of-the-science in diagnosis, staging, and therapeutic management of solid tumor cancers
• Learn state-of-the-science in diagnosis, staging, and therapeutic management of hematologic cancers
• Understand recent treatment advances in solid tumor and hematologic oncology and their impact on modern clinical practice

This board review course is intended for medical oncology professionals, including physicians, nurses, pharmacists, fellows, and residents.

**MSK Course Directors**

**David H. Ilson, MD, PhD**
Attending Physician, Gastrointestinal Oncology Service
Division of Solid Tumor Oncology
Department of Medicine
Member, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College

**Paul A. Hamlin, MD**
Medical Director, David H. Koch Center for Cancer Care
Associate Attending, Lymphoma Service
Division of Hematologic Malignancies
Department of Medicine
Associate Professor of Medicine, Weill Cornell Medical College

Attendees will receive access to an online syllabus, which includes PDFs of the slides and recorded videos of the presentations.
Ghassan K. Abou-Alfa, MD, MBA
Attending Physician
Gastrointestinal Oncology Service

Carol Aghajanian, MD
Attending Physician, Chief
Gynecologic Medical Oncology Service

Dean F. Bajorin, MD, FACP
Attending Physician
Genitourinary Oncology Service
Frederick R. Adler Senior Faculty Chair

Renier J. Brentjens, MD, PhD
Director, Cellular Therapeutics Center
Attending Physician
Leukemia Service

Andrea Cercek, MD
Assistant Attending Physician
Gastrointestinal Oncology Service

Paul B. Chapman, MD
Attending Physician
Melanoma and Immunotherapeutics service

Hiram S. Cody III, MD, FACS
Attending Surgeon
Breast Service
Professor of Surgery, Weill Cornell Medical College

Chau T. Dang, MD
Regional Care Network Medical Site Director, MSK Westchester
Attending Physician
Breast Medicine Service

Mark A. Dickson, MD
Associate Attending Physician
Sarcoma Medical Oncology Service

Lara A. Dunn, MD
Assistant Attending Physician
Head and Neck Oncology Service

Darren R. Feldman, MD
Chair, Quality Assurance
Assistant Attending Physician
Genitourinary Oncology Service
Assistant Professor of Medicine, Weill Cornell Medical College

Devika Gajria, MD
Assistant Attending Physician
Breast Medicine Service

Mrinal M. Gounder, MD
Assistant Attending Physician
Sarcoma Medical Oncology Service

Rachel N. Grisham, MD
Associate Attending Physician
Gynecologic Medical Oncology Service

Christian Grommes, MD
Assistant Attending Physician
Brain Tumor Service

Malin Hultcrantz, MD, PhD
Assistant Attending Physician
Myeloma Service

W. Victoria Lai, MD
Assistant Attending Physician
Thoracic Oncology Service

Simon Mantha, MD, MPH
Attending Physician
Hematology Service

Anthony Mato, MD
Director, CLL Program
Associate Attending Physician
Leukemia Service

Michael J. Mauro, MD
Leader, Myeloproliferative Neoplasms Program
Attending Physician
Leukemia Service

Beryl McCormick, MD, FACR
Chief, Attending Physician
External Beam Radiotherapy Service
Professor of Radiation Oncology, Weill Cornell Medical College

Jodi Mones, MD
Associate Attending
Hematology Service

Alison Moskowitz, MD
Clinical Director, Lymphoma Inpatient Unit
Associate Attending
Lymphoma Service

Robert J. Motzer, MD
Attending Physician
Genitourinary Oncology Service
Jack and Dorothy Byrne Chair in Clinical Oncology

Eileen M. O’Reilly, MD
Associate Director, David M. Rubenstein Center for Pancreatic Cancer
Attending Physician, Member
Gastrointestinal Oncology Service
Winthrop Rockefeller Chair in Medical Oncology
Professor of Medicine, Weill Cornell Medical College

Rekha Parameswaran, MD
Attending Physician
Hematology Service

Gregory J. Riely, MD, PhD
Vice Chair, Clinical Research
Associate Attending Physician
Thoracic Oncology Service

Leonard B. Saltz, MD
Executive Director for Clinical Value and Sustainability
Attending Physician
Gastrointestinal Oncology Service
Professor of Medicine, Weill Cornell Medical College

Rachel Sanford, MD
Assistant Attending Physician
Breast Medicine Service

Craig S. Sauter, MD
Clinical Director, Associate Attending
Adult Bone Marrow Transplant Service

Susan K. Seo, MD
Director, Antibiotic Management Program
Attending Physician
Infectious Disease service

Susan F. Slovin, MD, PhD
Attending Physician
Genitourinary Oncology Service
Associate Chair, Academic Administration

Zsofia K. Stadler, MD
Clinical Director, Clinical Genetics Service
Associate Attending Physician
Clinical Genetics and Gastrointestinal Oncology Services

Martin S. Tallman, MD
Chief, Leukemia Service

Anna M. Varghese, MD
Assistant Attending Physician
Gastrointestinal Oncology Service

Cy Wilkins, MD
Assistant Attending
Hematology Service

Marjorie G. Zauderer, MD
Co-Director MSK Mesothelioma Program
Associate Attending Physician
Thoracic Oncology Service

Andrew D. Zelenetz, MD, PhD
Medical Director, Quality Informatics
Attending Physician
Lymphoma Service
### Friday, March 12, 2021

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 AM</td>
<td>Virtual Course Check-in</td>
<td></td>
</tr>
<tr>
<td>9:10 AM</td>
<td>Welcome and Introduction</td>
<td>David H. Ilson, MD, PhD</td>
</tr>
<tr>
<td>9:15 AM</td>
<td>Colon Cancer</td>
<td>Leonard B. Saltz, MD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Melanoma</td>
<td>Paul B. Chapman, MD</td>
</tr>
<tr>
<td>10:45 AM</td>
<td>Prostate Cancer</td>
<td>Susan F. Slovin, MD, PhD</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Kidney Cancer</td>
<td>Robert J. Motzer, MD</td>
</tr>
<tr>
<td>12:15 PM</td>
<td>Mesothelioma</td>
<td>Marjorie G. Zauderer, MD</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>Lunch Break</td>
<td></td>
</tr>
<tr>
<td>1:15 PM</td>
<td>Urothelial Cancer</td>
<td>Dean F. Bajorin, MD, FACP</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Testis Cancer</td>
<td>Darren R. Feldman, MD</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Uterine/Cervix/Other GYN Cancers</td>
<td>Carol Aghajanian, MD, MD</td>
</tr>
<tr>
<td>3:30 PM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>3:45 PM</td>
<td>Ovarian Cancer</td>
<td>Rachel N. Grisham, MD, MD</td>
</tr>
<tr>
<td>4:30 PM</td>
<td>Breast Cancer: Surgery</td>
<td>Hiram S. Cody III, MD, FACS</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Breast Cancer: Radiation Therapy</td>
<td>Beryl McCormick, MD, FACR</td>
</tr>
<tr>
<td>5:30 PM</td>
<td>Esophageal and Gastric Cancer</td>
<td>David H. Ilson, MD, PhD</td>
</tr>
<tr>
<td>6:15 PM</td>
<td>Closing Remarks and Adjourn</td>
<td>David H. Ilson, MD, PhD</td>
</tr>
</tbody>
</table>

### Saturday, March 13, 2021

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 AM</td>
<td>Virtual Course Check-in</td>
<td></td>
</tr>
<tr>
<td>6:55 AM</td>
<td>Welcome and Introduction</td>
<td>David H. Ilson, MD, PhD</td>
</tr>
<tr>
<td>7:00 AM</td>
<td>Small Cell Lung Cancer</td>
<td>W. Victoria Lai, MD</td>
</tr>
<tr>
<td>7:30 AM</td>
<td>Breast Cancer: Adjuvant Therapy</td>
<td>Chau T. Dang, MD</td>
</tr>
<tr>
<td>8:30 AM</td>
<td>Breast Cancer: Advanced Disease</td>
<td>Rachel Sanford, MD, MD</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>Breast Cancer: Hormonal Therapy</td>
<td>Devika Gajria, MD, MD</td>
</tr>
<tr>
<td>12:30 AM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:45 AM</td>
<td>Hepatocellular Cancer and Cholangiocarcinoma</td>
<td>Ghassan K. Abou-Alfa, MD, MBA</td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Pancreatic and Neuroendocrine Cancer</td>
<td>Eileen M. O’Reilly, MD</td>
</tr>
<tr>
<td>12:15 PM</td>
<td>Lunch Break</td>
<td></td>
</tr>
<tr>
<td>1:15 PM</td>
<td>Non Small Cell Lung Cancer</td>
<td>Gregory J. Riely, MD, PhD</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Head and Neck, Thyroid, and Non Melanoma Skin Cancer</td>
<td>Lara A. Dunn, MD, PhD</td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Anal/Rectal Cancer</td>
<td>Andrea Cercek, MD, MD</td>
</tr>
<tr>
<td>3:30 PM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>3:45 PM</td>
<td>Genetics</td>
<td>Zsofia K. Stadler, MD, MD</td>
</tr>
<tr>
<td>4:15 PM</td>
<td>CNS Tumors</td>
<td>Christian Grommes, MD, MD</td>
</tr>
<tr>
<td>4:45 PM</td>
<td>Sarcoma</td>
<td>Mark A. Dickson, MD, MD</td>
</tr>
<tr>
<td>5:15 PM</td>
<td>Infectious Disease</td>
<td>Susan K. Seo, MD, MD</td>
</tr>
<tr>
<td>5:45 PM</td>
<td>Closing Remarks and Adjourn</td>
<td>David H. Ilson, MD, PhD</td>
</tr>
</tbody>
</table>
**Live Virtual Schedule**

**Sunday, March 14, 2021**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45 AM</td>
<td>Virtual Course Check-in</td>
<td></td>
</tr>
<tr>
<td>7:00 AM</td>
<td><strong>Welcome and Introduction</strong></td>
<td>Paul A. Hamlin, MD</td>
</tr>
<tr>
<td>7:05 AM</td>
<td><strong>Pharmacology</strong></td>
<td>Mrinal M. Gounder, MD</td>
</tr>
<tr>
<td>9:20 AM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>9:30 AM</td>
<td><strong>CAR T cells</strong></td>
<td>Renier J. Brentjens, MD, PhD</td>
</tr>
<tr>
<td>10:30 AM</td>
<td><strong>Low Grade NHL</strong></td>
<td>Andrew D. Zelenetz, MD, PhD</td>
</tr>
<tr>
<td>11:00 AM</td>
<td><strong>CLL/SLL</strong></td>
<td>Anthony Mato, MD</td>
</tr>
<tr>
<td>11:30 AM</td>
<td><strong>DLBCL/MCL/BL</strong></td>
<td>Paul Hamlin, MD</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>Lunch Break</td>
<td></td>
</tr>
<tr>
<td>1:15 PM</td>
<td><strong>HL/T Cell</strong></td>
<td>Alison Moskowitz, MD</td>
</tr>
<tr>
<td>2:15 PM</td>
<td><strong>Auto/Allo</strong></td>
<td>Craig Sauter, MD</td>
</tr>
<tr>
<td>3:15 PM</td>
<td><strong>AML/ALL</strong></td>
<td>Martin S. Tallman, MD</td>
</tr>
<tr>
<td>4:15 PM</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>5:30 PM</td>
<td><strong>MDS/MPN</strong></td>
<td>Michael J. Mauro, MD</td>
</tr>
<tr>
<td>6:30 PM</td>
<td><strong>Myeloma/Amyloid</strong></td>
<td>Malin Hultcrantz, MD, PhD</td>
</tr>
<tr>
<td>7:00 PM</td>
<td><strong>Closing Remarks and Adjourn</strong></td>
<td>Paul A. Hamlin, MD</td>
</tr>
</tbody>
</table>

**Monday, March 15, 2021**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45 AM</td>
<td>Virtual Course Check-in</td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td><strong>Welcome and Introduction</strong></td>
<td>Paul A. Hamlin, MD</td>
</tr>
<tr>
<td>8:05 AM</td>
<td><strong>Approach to The Bleeding Patient</strong></td>
<td>Rekha Parameswaran, MD</td>
</tr>
<tr>
<td>9:00 AM</td>
<td><strong>The Role of the New Direct Oral Anticoagulants in Practice</strong></td>
<td>Simon Mantha, MD, MPH</td>
</tr>
<tr>
<td>10:00 AM</td>
<td><strong>Thrombocytopenia, ITP and Beyond</strong></td>
<td>Cy Wilkins, MD</td>
</tr>
<tr>
<td>11:00 AM</td>
<td><strong>Sickle Cell Disease, Thalassemia</strong></td>
<td>Jodi Mones, MD</td>
</tr>
<tr>
<td>12:00 PM</td>
<td><strong>Closing Remarks and Adjourn</strong></td>
<td>Paul A. Hamlin, MD</td>
</tr>
</tbody>
</table>

**Live Virtual Format**

This live virtual program will be delivered using Zoom. CME credit and ABIM MOC points will be offered for this live virtual program. Detailed access and credit instructions will be emailed to attendees prior to the start of the course.
REGISTER ONLINE:
mskcc.org/hemoncboardreview

Live Virtual Registration Fees

<table>
<thead>
<tr>
<th>Category</th>
<th>Fee</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians (MDs, PhDs, and DOs)</td>
<td>$1,500</td>
</tr>
<tr>
<td>Residents, Fellows, Nurses, and Other Healthcare Providers</td>
<td>$975</td>
</tr>
<tr>
<td>Industry Professionals*</td>
<td>$2,625</td>
</tr>
</tbody>
</table>

Registration Discounts/Promotions

- MSK CME offers a discounted rate for MSK Alumni, MSK Cancer Alliance and Cancer Care Partners.
- MSK employee registration is complimentary; however, you must complete course registration in order to attend this course.

For additional details on registration, including the MSK CME cancellation policy, please visit the course website: mskcc.org/hemoncboardreview

*Industry professionals may attend MSK CME activities for their own education. Marketing, sales, and promotion of products and services is strictly prohibited at MSK CME activities.

Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this enduring material activity for a maximum of 31.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 31.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Faculty Disclosure

It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it provides as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity provided by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.
“Excellent program with great online content.”

“I thought the program was top notch. It covered the field very comprehensively and your lecturers were overall top rate.”

“This was the first board review course I attended and felt it was the best I could have attended.”

“Excellent course. I will attend next year.”

mskcc.org/hemoncboardreview